Combination of Osimertinib and Chemotherapy Enhances Progression-Free Survival in EGFR-Mutated Non-Small Cell Lung Cancer
Combining osimertinib with chemotherapy significantly extends progression-free and overall survival in patients with EGFR-mutated non-small cell lung cancer, according to recent clinical trial results.
Recent findings presented at the 2025 World Conference on Lung Cancer highlight the benefits of combining osimertinib with chemotherapy for patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR mutations. The COMPEL trial, a global double-blind study, evaluated patients who experienced non-central nervous system (CNS) disease progression on first-line osimertinib. Participants were randomized to receive either continued osimertinib alongside platinum-based chemotherapy or placebo with chemotherapy.
The study demonstrated that patients receiving osimertinib in combination with chemotherapy had a significantly longer progression-free survival (PFS), with a median of 8.4 months compared to 4.4 months in the placebo group. The hazard ratio for disease progression was 0.43, indicating a substantial reduction in risk. Additionally, overall survival was improved, with median overall survival reaching 15.9 months for the combination group versus 9.8 months for placebo plus chemotherapy.
Lead researcher Dr. Giulia Pasello from the Veneto Institute of Oncology explained that some tumor cells remain sensitive to continued osimertinib, supporting its use as a backbone treatment strategy in this setting. The combination therapy was well-tolerated, with safety profiles consistent with known effects of the individual agents. These promising results align with the findings from the FLAURA2 study, further emphasizing the potential of integrating osimertinib with chemotherapy for better patient outcomes.
This research underscores the importance of personalized treatment plans for patients with EGFR-mutated NSCLC post-progression, offering a new avenue to prolong disease control and improve survival rates.
Source: https://medicalxpress.com/news/2025-09-osimertinib-chemotherapy-free-survival-egfr.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Identification of Two Biomarkers That Could Predict Healing Outcomes in Diabetic Foot Ulcers
A groundbreaking study identifies two biomarkers, c-myc and p-GR, with potential to predict healing outcomes in diabetic foot ulcers, paving the way for improved patient management.
How Exercise Intensity Affects Your Gut Microbiome
Recent research shows that the intensity of exercise can impact gut microbiome health, influencing athletes' performance and well-being. Discover how training load and diet affect gut bacteria in this comprehensive overview.
What Makes 'Superager' Brains More Resistant to Aging?
Discover the unique brain features of superagers—elderly individuals who maintain youthful cognition—and what this means for future brain health interventions.
Innovative Blood Test Offers Non-Invasive Diagnosis of Celiac Disease
A revolutionary blood test called WBAIL-2 shows promise in diagnosing celiac disease non-invasively, even for those on a gluten-free diet, potentially transforming current diagnostic practices.